SCHEMBL6774135

SCHEMBL6774135

O=C1c2ccccc2C(=O)N1CCCCC(O)CO

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 5/20 0.53
HDAC7 Q8WUI4 5/20 0.53
ALDH1A1 P00352 2/20 0.52
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
HDAC8 Q9BY41 3/20 0.50
HDAC3 O15379 2/20 0.50
HDAC4 P56524 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
HDAC9 Q9UKV0 2/20 0.50
HDAC5 Q9UQL6 2/20 0.50
MAOB P27338 1/20 0.48
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 1/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20707259 1.00 HDAC1 (0.53) HDAC1HDAC7ALDH1A1TDP1L3MBTL1
SCHEMBL6779279 0.98 TDP1 (0.54) HDAC1HDAC7ALDH1A1TDP1L3MBTL1
SCHEMBL6778346 0.98 TDP1 (0.54) HDAC1HDAC7ALDH1A1TDP1L3MBTL1
SCHEMBL751414 0.95 ALDH1A1 (0.54) HDAC1HDAC7ALDH1A1TDP1L3MBTL1
SCHEMBL368756 0.88 ALDH1A1 (0.65) ALDH1A1RAB9ASMN1; SMN2MAPTNPC1
SCHEMBL10673491 0.86 TDP1 (0.54) HDAC1HDAC7ALDH1A1TDP1L3MBTL1
SCHEMBL16392601 0.82 ACHE (0.60) MAOB
SCHEMBL8019454 0.82 KMT2A (0.53) HDAC1HDAC7ALDH1A1HDAC8HDAC3
SCHEMBL17280821 0.82 MAOB (0.56) HDAC1HDAC7MAOBMEN1KMT2A
SCHEMBL17267477 0.81 HDAC7 (0.64) HDAC1HDAC7ALDH1A1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3438155-B1 BIODEGRADABLE HYDROGEL HAVING CYCLIC BENZYLIDENE ACETAL STRUCTURE NOF CORP (JP) 2023-09-06 EP disclosed
US-11529423-B2 Biodegradable polyethylene glycol derivative having cyclic benzylidene acetal linker NOF CORPORATION (JP) 2022-12-20 US disclosed
US-11530295-B2 Hydrophilic polymer derivative having cyclic benzylidene acetal linker NOF CORPORATION (JP) 2022-12-20 US disclosed
US-11041052-B2 Biodegradable hydrogel having cyclic benzylidene acetal structure NOF CORPORATION (JP) 2021-06-22 US disclosed
EP-3130587-B1 HYDROPHILIC POLYMER DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORP (JP) 2021-06-16 EP disclosed
EP-3357514-B1 LIPID DERIVATIVE IN WHICH HYDROPHILIC POLYMER IS BOUND VIA CYCLIC BENZYLIDENE ACETAL LINKERS NOF CORP (JP) 2021-04-14 EP disclosed
EP-3279236-B1 BIODEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORP (JP) 2021-01-06 EP disclosed
US-10808050-B2 Antibody-drug conjugate having cyclic benzylidene acetal linker NOF CORPORATION (JP) 2020-10-20 US disclosed
US-20200291178-A1 HYDROPHILIC POLYMER DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORPORATION (JP) 2020-09-17 US disclosed
US-20200289656-A1 BIODEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORPORATION (JP) 2020-09-17 US disclosed
US-20170290919-A1 ANTIBODY-DRUG CONJUGATE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORPORATION (JP) 2017-10-12 US disclosed
US-20170107325-A1 HYDROPHILIC POLYMER DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORPORATION (JP) 2017-04-20 US disclosed
US-20170107325-A1 HYDROPHILIC POLYMER DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORPORATION (JP) 2017-04-20 US disclosed
EP-3130587-A1 HYDROPHILIC POLYMER DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF Corporation (JP) 2017-02-15 EP disclosed
US-6693105-B1 USING XANTHINYL DERIVATIVES TO REDUCE TREATMENT INDUCED TOXICITY; INHIBITING CELLULAR SIGNALING THROUGH SECOND MESSENGER PATHWAY; REDUCING CELLULAR LEVEL OF NONARACHI-DONATE PHOSPHATIDIC ACID AND DIACYLGLYCEROL CELL THERAPEUTICS, INC. 2004-02-17 US disclosed
US-6133274-A TREATING DISEASE MEDIATED BY INTRACELLULAR SIGNALING THROUGH ONE OR TWO SPECIFIC INTRACELLULAR SIGNALING PATHWAYS; A XANTHINYL HAVING AT LEAST ONE NITROGEN SUBSTITUTED BY AN HYDROXYALKYL; ANTITUMOR,-CARCINOGENIC,-ARTHRITIC AGENTS CELL THERAPEUTICS, INC. (US) 2000-10-17 US disclosed
US-5780476-A ADMINISTERING TO TREAT INFLAMMATORY DISEASE AND RHEUMATOID ARTHITIS CELL THERAPEUTICS, INC. (US) 1998-07-14 US disclosed
EP-0669825-A4 HYDROXYL-CONTAINING COMPOUNDS. CELL THERAPEUTICS INC (US) 1996-04-03 EP disclosed
EP-0669825-A1 HYDROXYL-CONTAINING COMPOUNDS CELL THERAPEUTICS, INC. (US) 1995-09-06 EP disclosed
WO-1994011001-A1 HYDROXYL-CONTAINING COMPOUNDS CELL THERAPEUTICS, INC. (US) 1994-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200291178-A1 HYDROPHILIC POLYMER DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER H1-2, H1-0, H1-3 HDAC1 24/4885HDAC7 568/4885ALDH1A1 894/4885
US-11529423-B2 Biodegradable polyethylene glycol derivative having cyclic benzylidene acetal linker AMDHD2, PGD, TREH HDAC1 32/4885HDAC7 44/4885ALDH1A1 405/4885
US-10808050-B2 Antibody-drug conjugate having cyclic benzylidene acetal linker H1-2, CD22, H1-0 HDAC1 53/4885HDAC7 350/4885ALDH1A1 399/4885
US-11041052-B2 Biodegradable hydrogel having cyclic benzylidene acetal structure H1-0, H1-2, H1-4 HDAC1 20/4885HDAC7 183/4885ALDH1A1 99/4885
US-20170290919-A1 ANTIBODY-DRUG CONJUGATE HAVING CYCLIC BENZYLIDENE ACETAL LINKER H1-2, CD22, H1-0 HDAC1 53/4885HDAC7 350/4885ALDH1A1 399/4885
US-11530295-B2 Hydrophilic polymer derivative having cyclic benzylidene acetal linker H1-2, H1-0, H1-3 HDAC1 24/4885HDAC7 568/4885ALDH1A1 894/4885
US-20200289656-A1 BIODEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER AMDHD2, PGD, TREH HDAC1 32/4885HDAC7 44/4885ALDH1A1 405/4885
US-20170107325-A1 HYDROPHILIC POLYMER DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER H1-2, H1-0, H1-3 HDAC1 25/4885HDAC7 550/4885ALDH1A1 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.